Silence Therapeutics plc (SLN) Financials

Silence Therapeutics plc (SLN) is a biotechnology company specializing in the development and commercialization of RNA-based therapeutics. The company's financials provide insight into its performance and financial health. The income statement shows the company's revenue and expenses over a specific period. It reveals Silence Therapeutics' net income from stockholders, gross profit, and total revenue. These figures reflect the company's profitability and revenue generation capabilities.

The balance sheet provides a snapshot of Silence Therapeutics' financial position at a specific point in time. It includes the company's total assets, total liabilities, and stockholders' equity. This information helps assess the company's financial stability and its ability to meet its financial obligations. Silence Therapeutics' cash equivalents and net debt also provide insights into its liquidity and leverage.

Cash flow statements detail the sources and uses of cash for Silence Therapeutics. The operating cash flow shows the cash generated from the company's core operations, while the investing cash flow and financing cash flow account for cash flows related to investments and financing activities. Silence Therapeutics' free cash flow is a measure of its ability to generate cash after accounting for capital expenditures.

As a publicly traded company, Silence Therapeutics' financials are crucial for investors and stakeholders to evaluate its financial performance and make informed decisions. These financial statements offer valuable insights into the company's revenue, expenses, profitability, liquidity, and financial health.